新闻发布

San Diego, CA, USA – June 4, 2018 – HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.

San Diego, CA, USA – January 18, 2017 –HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry

San Diego, CA, USA – March 24, 2016 –HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9^th BioPharma Asia Convention 2016.

Inhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy

San Diego, CA, USA – March 15, 2016 –HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.

卫材将在淋巴瘤领域实现沪亚产品的商业化并在实体瘤领域开发新的适应症

美国加州圣迭戈 – 2016年2月1日  –沪亚生物国际总裁、首席执行官、执行董事长和创始人Mireille Gillings博士宣布，日本卫材株式会社经由协议获得了HBI-8000在日本、韩国、泰国、马来西亚、印尼、菲律宾、越南和新加坡的独占许可。